This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 months of age) who may or may not have had prior respiratory syncytial virus (RSV) infection.
Respiratory Syncytial Virus Infections
This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 months of age) who may or may not have had prior respiratory syncytial virus (RSV) infection.
A Study of BLB-201 RSV Vaccine in Infants and Children
-
Paradigm Clinical Research, La Mesa, California, United States, 91942
Peninsula Research Associates, Rolling Hills Estates, California, United States, 90274
Velocity Clinical Research, Boise, Meridian, Idaho, United States, 83642
Clinical Research Prime, Rexburg, Idaho, United States, 83440
AMR Newton, Newton, Kansas, United States, 67114
Velocity Clinical Research - Lafayette, Lafayette, Louisiana, United States, 70508
Great Lakes Research Institute, Southfield, Michigan, United States, 48075
Velocity Clinical Research, Hastings, Hastings, Nebraska, United States, 68901
Velocity Clinical Research, Cleveland, Beachwood, Ohio, United States, 44122
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, 45229
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
6 Months to 5 Years
ALL
Yes
Blue Lake Biotechnology Inc.,
Paul Spearman, MD, PRINCIPAL_INVESTIGATOR, Children's Hospital Medical Center, Cincinnati
2024-12-23